Nyheter
Big Biotech in the Bargain Bin
Big Biotech in the Bargain Bin The sell-off in biotech stocks that began last summer has resulted in valuations that are on par with and in some cases lower than those seen in the broad equity market (at this writing, 2/17/16). Biotech valuations have not dipped this low since the aftermath of the 2007-2008 financial crisis. For investors with an appetite for biotech, this may provide a bargain-priced opportunity.
Since 2005 U.S. biotech stocks have traded at higher earnings multiples than the broader S&P 500® Index. Over the last 10 years biotech stocks have had an average price-earnings (P/E) ratio of 23.3 versus 16.2 for the S&P 500 Index. Today those metrics are nearly equivalent in the 16 P/E range. A number of large-cap biotech companies have traded below general market valuations, e.g., Amgen (AMGN), which traded at 16.2x earnings and Gilead Sciences (GILD) at 7.7x earnings, as of 2/17/16. By comparison, Market Vectors® Biotech ETF (BBH) has a P/E ratio of 18.6 as of 2/17/16. BBH seeks to track the Market Vectors U.S. Listed Biotech 25 Index, which is comprised of the 25 largest and most liquid U.S.-listed biotech stocks.
P/Es of Biotech Stocks Fall Below P/E of Broader U.S. Equities
Historical Averages 12/31/2005 – 2/17/2016
(Click to enlarge) Past performance is no guarantee of future results. Index performance is not illustrative of fund performance.
While pricing concerns, weakness in emerging markets currencies, and the strength of the U.S. dollar may have contributed to weakness in biotech, there may be better news down the road. The expected total number of upcoming clinical trials, new drug applications, and new biologics up for approval is 32% higher now than five years ago.1 As the global population ages, demand for drugs is growing. Additionally, the current price environment may compel large biotech companies with healthy cash balances to grow their businesses through acquisitions or engage in share buyback programs; such activity could support share prices.
Amidst these trends, investors may consider targeting large biotech companies via an exchange-traded fund such as Market Vectors Biotech ETF ( BBH) to potentially capture value in the biotech industry.
Sources: VanEck, FactSet and Bloomberg. Data as of 2/17/2016.
ETFs is authored by VanEck thought leaders. VanEck is the sponsor of Market Vectors ETFs and is currently among the largest providers of exchange traded funds (ETFs) in the U.S. and worldwide. Market Vectors ETFs empower investors to help build better portfolios with access to compelling investment themes and strategies. Our ETFs span many global asset classes, and are built to be transparent, liquid, and pure-play reflections of target markets.
Authored by Gabor Gurbacs, ETF Data Analyst
IMPORTANT DISCLOSURE
1 Source: Bloomberg and VanEck ETF Research
Index Descriptions: (i) The S&P 500 (The Standard & Poor’s 500) Index is an American stock market index based on the market capitalizations of 500 large companies having common stock listed on the NYSE or NASDAQ. (ii) The S&P 500 Biotechnology Index represent the biotechnology sub-industry segment of the S&P 500 Index. (iii) The Market Vectors® US Listed Biotech 25 Index comprises of the 25 largest and most liquid U.S. listed biotech companies.
Price/Earnings Ratio is the price of a security divided by the earnings per share of the security.
I början av året förutspådde 21shares att krypto-ETPer skulle driva ytterligare institutionell adoption och nå 250 miljarder dollar i förvaltat kapital globalt. Den milstolpen har just nåtts.
Research Newsletter
Each week the 21Shares Research team will publish our data-driven insights into the crypto asset world through this newsletter. Please direct any comments, questions, and words of feedback to research@21shares.com
Disclaimer
The information provided does not constitute a prospectus or other offering material and does not contain or constitute an offer to sell or a solicitation of any offer to buy securities in any jurisdiction. Some of the information published herein may contain forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those in the forward-looking statements as a result of various factors. The information contained herein may not be considered as economic, legal, tax or other advice and users are cautioned to base investment decisions or other decisions solely on the content hereof.
Globala krypto-ETPer förvaltade tillgångar når 250 miljarder dollar
YGLD ETP spårar priset på guld och ger en löpande avkastning
Investera i Stacks med en börshandlad produkt
VALOUR FLR SEK följer priset på kryptovalutan FLR
BlackRock utökar sitt utbud av iShares iBonds UCITS ETFer med sex nya lanseringar
HANetf och Infrastructure Capital Advisors samarbetar för att lansera aktivt förvaltad preferensavkastnings-ETF i Europa
IN0A ETF spårar S&P 500 med fokus på företag med höga ESG-betyg
De bästa lågvolatilitets ETFer på marknaden
PLTY ETP utfärdar optioner mot aktier i Palantir
Time in Bitcoin beats timing Bitcoin
-
Nyheter4 veckor sedanHANetf och Infrastructure Capital Advisors samarbetar för att lansera aktivt förvaltad preferensavkastnings-ETF i Europa
-
Nyheter4 veckor sedanIN0A ETF spårar S&P 500 med fokus på företag med höga ESG-betyg
-
Nyheter3 veckor sedanDe bästa lågvolatilitets ETFer på marknaden
-
Nyheter4 veckor sedanPLTY ETP utfärdar optioner mot aktier i Palantir
-
Nyheter4 veckor sedanTime in Bitcoin beats timing Bitcoin
-
Nyheter4 veckor sedanHANetf kommenterar kopparuppgången
-
Nyheter2 veckor sedanFokus mot en helt ny börshandlad produkt i september 2025
-
Nyheter3 veckor sedanM5TYs senaste utdelningstakt (55 %) belyser covered call-strategins inkomstpotential
